Home

MARK CORRIGAN

CIK 1250661 · President & CEO · last filed 2025-12-10

MARK CORRIGAN is a President & CEO who has filed 60 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $217.3K of WVE on Dec 10, 2025. Across all open-market trades the lifetime net is −$9.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $169.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$169.7K

Companies

10

Total Filings

60

Lifetime Open-Market Net

-$9.41M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
WVE Director 28,815 $5.89 $169.7K -$217.3K 8 2025-12-10
TREVENA INC (TRVN) Delisted Director — $0.01 — $0 2 2024-06-14
Nabriva Therapeutics plc (NBRV) Delisted Director 288 $1.42 $409 -$2.0K 6 2022-08-04
NOVELION THERAPEUTICS INC. (NVLN) Delisted Director — — — $0 3 2018-08-13
CoLucid Pharmaceuticals, Inc. (CLCD) Delisted Director — — — $0 3 2017-03-01
EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted Director 21,859 — — $0 2 2015-06-08
CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted Director 0 — — -$400.0K 2 2015-01-21
CUBIST PHARMACEUTICALS INC (CBST) Delisted Director 5,498 — — -$1.17M 9 2013-06-14
EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted President & CEO 87,205 — — $0 3 2010-03-03
SEPRACOR INC /DE/ (SEPR) Delisted Executive VP, R&D 70,668 — — -$7.62M 10 2009-10-19

Recent Filings

60 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-10 WVE Sell (S) −16,115 -$217.3K EDGAR
2025-12-08 WVE Notice (144) −16,115 -$120.7K EDGAR
2025-08-13 WVE Grant (A) +12,700 $0 EDGAR
2024-08-14 WVE Grant (A) +32,230 $0 EDGAR
2024-06-14 TREVENA INC (TRVN) Delisted Grant (A) — $0 EDGAR
2023-08-09 WVE Grant (A) — $0 EDGAR
2023-07-20 TREVENA INC (TRVN) Delisted Grant (A) — $0 EDGAR
2022-08-17 WVE Grant (A) — $0 EDGAR
2022-08-04 Nabriva Therapeutics plc (NBRV) Delisted Sell (S) −10,297 -$2.0K EDGAR
2021-08-18 WVE Grant (A) — $0 EDGAR
Showing 1–10 of 60
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.